ABVC BioPharma
ABVC
9 hedge funds and large institutions have $304K invested in ABVC BioPharma in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.02% less ownership
Funds ownership: 0.2% → 0.18% (-0.02%)
28% less capital invested
Capital invested by funds: $421K → $304K (-$117K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAG
Spotlight Asset Group
Oakbrook Terrace,
Illinois
|
+$665 |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$419 |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$253 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$24.5K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$13.5K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8.77K |
| 4 |
Two Sigma Investments
New York
|
-$1.86K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $201K | – | – | – |
|
2
Geode Capital Management
Boston,
Massachusetts
| $71K | – | – | – |
|
|
3
Two Sigma Investments
New York
| $11.5K | -$1.86K | -280 | -11% |
|
4
Northern Trust
Chicago,
Illinois
| $9.57K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $7.22K | +$419 | +63 | +5% |
|
|
6
BlackRock
New York
| $3.02K | -$24.5K | -3,684 | -86% |
|
|
SAG
7
Spotlight Asset Group
Oakbrook Terrace,
Illinois
| $520 | +$665 | +100 | New |
|
|
8
Wells Fargo
San Francisco,
California
| $67 | +$7 | +1 | +8% |
|
|
TSS
9
Two Sigma Securities
New York
| – | -$13.5K | -2,107 | Closed |
|
|
10
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$8.77K | -1,392 | Closed |
|
|
11
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$253 | +38 | New |
|
ABVC Hedge Fund Activity: Q2 2023 in Review
9 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q2 2023, worth a combined $304K — down 28% from $421K a quarter earlier.
Fund positioning in ABVC was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Spotlight Asset Group, opening a new position worth an estimated $665. The largest seller was BlackRock, cutting an estimated $24.5K.
- 9 institutional investors held ABVC BioPharma (ABVC) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $304K of ABVC BioPharma stock for Q2 2023, down 28% quarter-over-quarter.
- 2 funds opened new ABVC BioPharma positions in Q2 2023 and 2 closed out, a net change of 0 holders.
- The largest ABVC BioPharma buyer in Q2 2023 was Spotlight Asset Group, an estimated $665 added.
- The largest ABVC BioPharma seller in Q2 2023 was BlackRock, an estimated $24.5K sold.
Based on aggregated 13F filings for Q2 2023.